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Abstract
The American College of Radiology (ACR) and the American
College of Cardiology Foundation (ACCF) have jointly de-
veloped a method to define appropriate utilization of cardio-
vascular imaging. The primary role of this method is to create
a series of documents to define the utility of cardiovascular
imaging procedures in relation to specific clinical questions,
with the aim of defining what, if any, imaging tests are
indicated to help to determine diagnosis, treatment, or out-
come. The methodology accomplishes this aim through the
application of systematic evidence reviews integrated with
expert opinion by means of a rigorous Delphi process. By
obtaining broad input during the development process from
radiologists, cardiologists, primary care physicians, and other
stakeholders, these documents are intended to provide practical
evidence-based guidance to ordering providers, imaging laborato-
ries, interpreting physicians, patients, and policymakers as to
optimal cardiovascular imaging utilization. This document details
the history, rationale, and methodology for developing these joint
documents for appropriate utilization of cardiovascular imaging.
Introduction
Cardiovascular imaging procedures provide essential infor-
mation for the detection, diagnosis, and management of
disease, and serve a vital role in risk assessment and clinical
decision making. The relevant procedures include echocar-
diography, radionuclide imaging, cardiac magnetic reso-
nance, cardiac computed tomography, and invasive coronary
angiography. The optimal use of these procedures for
specific clinical scenarios is unclear and provides the nidus
for the development of appropriate use recommendations.
Over the last decade, there has been a tremendous growth in
the use of imaging, disproportionate to the growth of other
components of healthcare spending. This has led to scrutiny
of all medical imaging and, in particular, imaging related to
cardiovascular care. The reasons for the growth of imaging
are many: however, perceived improvement in patient care
by both providers and patients is a driving factor. At the
same time, appropriate utilization has been questioned due
to the geographic variability in the use of cardiovascular
imaging procedures, unexplained by differences in patient
demographics or risk factors (1,2). In an effort to contain the
growth and associated costs of cardiac imaging, payers have
adopted various approaches, including prior authorization,
in an effort to limit testing. A crucial concern is that these
controls may limit patient access to the appropriate imaging
procedures and/or direct patients to higher cost through
delay in diagnosis or layered testing diagnostic approaches.
Additionally, pre-authorization frequently relies on propri-
etary algorithms, is inconsistent with published literature
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Clinical guidelines and performance measures have been
successfully developed for years, and their positive impact on
patient outcomes has been well demonstrated. However, the
evaluation of the impact of diagnostic tests on patient
outcomes presents unique challenges (3). Methods and
funding to evaluate diagnostic testing have lagged behind
those related to treatments (4). In a similar manner, using
an appropriate testing strategy (i.e., clinical guidelines) is
increasingly recognized as an important determinant of
healthcare quality (5).
Historical Perspective
The American College of Cardiology Foundation (ACCF)
and American College of Radiology (ACR) have both
produced appropriate use guidance documents in an effort
to delineate recommended utilization of cardiovascular im-
aging. The ACR Task Force on Appropriateness Criteria
was created in 1993 to develop nationally accepted,
evidence-based, methodologically sound clinical guidelines,
called “appropriateness criteria,” to assist referring physi-
cians in making appropriate imaging decisions. These cri-
teria are developed beginning with a systematic critical
review of published literature on the topic. Ratings are
performed based on the evidence and supplemented by
expert opinion as needed, and then finalized using a
modified Delphi process. These ACR Appropriateness
Criteria (AC) are developed using a carefully defined,
reproducible methodology and cover the spectrum of diag-
nostic, interventional, and therapeutic procedures. Each AC
addresses a specific clinical scenario, generally with variants
as necessary, to address clinical reality. As of the June 2012
release, there are 180 ACR Appropriateness Criteria topics
addressing over 850 disease process variants (6). Each AC
document is updated every 2 years.
The ACCF has published clinical guidelines and perfor-
mance measures for more than 25 years, and in 2004,
initiated the development of appropriate use criteria in
conjunction with the ACR, the American Heart Associ-
ation, and cardiovascular subspecialty societies, in order
to provide physician-specific guidance when considering
utilization of cardiovascular imaging and other technol-
ogy. To date, these efforts have been modality specific for
imaging but have considered multiple technologies for
revascularization. The ACCF method also draws upon
the available evidence base and utilizes a modified Delphi
process to support a systematic evaluation of expert
opinion (7). As of 2010, 6 appropriate use documents,
each encompassing 50 to 200 clinical scenarios, have been
published (8–13).Goals
The primary goal of the current initiative is to harmonize
the separate efforts of the ACR and ACCF as related to
cardiovascular imaging and to provide consistent and au-
thoritative guidance to the healthcare community. The joint
effort by ACCF and ACR maintains a rigorous, but
transparent, methodology that includes the comparative and
multimodality imaging features of the ACR approach, as
well as the more specific set of clinical presentations
contained within the ACC method. This joint approach
uses the best elements of both societies’ approaches by
selecting clinical scenarios of high impact to patient care and
determining the cardiac imaging strategy that best provides
optimal and value-added patient care.
Definition of Appropriateness
Appropriateness methodology was initially described in the
1980s by RAND Corporation/University of California Los
Angeles as part of the Health Services Utilization Study
(14) (see Appendix A for additional details). The definition
or appropriate utilization is derived from the goals of the
QA alliance, a multistakeholder collaborative of physi-
ians and other healthcare providers, consumers, purchasers,
nd health plans focused on improved patient safety, health-
are quality, and value (15,16). The new method adheres to
he following definition: “The concept of appropriateness,
s applied to health care, balances risk and benefit of a
reatment, test, or procedure in the context of available
esources for an individual patient with specific character-
stics. Appropriateness criteria should provide guidance to
upplement the clinician’s judgment as to whether a patient
s a reasonable candidate for the given treatment, test, or
rocedure.” (16, para. 2). From conception to publication,
he joint ACR/ACCF process adheres to the aforemen-
ioned goals, with each document on appropriate utiliza-
ions of cardiovascular imaging based, to as great an extent
s possible, on available high-quality clinical data, supple-
ented as necessary by expertise and insights from other
ources. The process is represented in Figure 1.
Organizational Structure
The success of the process relies on the oversight committee
and staff to assemble physicians who are experts in the
clinical conditions and/or in imaging modalities, to form the
writing panels, review panels, and rating panels in a way that
will produce balanced recommendations based on the peer-
reviewed evidence that do not favor any specific approach or
discipline (Table 1).
1. The Oversight Committee provides methodological
oversight, defines the scope of documents, and sup-
ports continuity across panels and among documents.
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select individuals to serve on the writing, review, and
rating panels, and for providing review and approval
at each stage of the process.
2. The Writing Panel identifies clinical indications and
scenarios that are relevant for clinical decision making
and the use of cardiovascular imaging. The writing
Oversight Commiee Topic Selecon
Panel Formaon
Acvity Oversight
Wring Panel 
Review Panel 
Rang Panel 
Review Materials Developed by
Wring Panel
Literature Review
Clinical Scenarios and Narrave
Development
Round 1 Rang
Round 2
Round 3 (If Needed) or Teleconference
In-Person Meeng
Wring Panel Finalize Document
Oversight Commiee Society Endorsements and Publicaon
Figure 1. Organizational Structure for ACR/ACCF Appropriateness
Criteria Process
Table 1. Oversight Committee and Panel Membership Criteria
Name Number of Members
Oversight committee 12–16 Equal representation from ACC
Writing panel 6–10 Equal representation of imagin
included on the writing pan
medicine, health economics
Review panel 20–40 Content experts and stakehold
medical specialty organizat
Rating panel 15–19 Cardiology, radiology, physicia
are to comprise no more th
to ensure adequate clinical
Overall total 53–85 Cardiology, radiology, physiciaACCF  American College of Cardiology Foundation; ACR  American College of Radiology.panel systematically evaluates and categorizes litera-
ture with respect to each indication/scenario. The
panel constructs a narrative summary of the evidence
and accompanying evidence tables for each indication/
scenario relative to the application of cardiovascular
imaging modalities.
3. The Review Panel provides critical review and rec-
ommendations on refining the indications/scenarios,
narratives, literature cited, and evidence tables before
the rating process.
4. The Rating Panel reviews the prepared narratives and
evidence tables, and rates the appropriateness of the
use of imaging for the specific clinical indications. The
panel performs an initial round of rating followed by
an in-person meeting to discuss and further refine the
indications and evidence, if needed. A second, and
possibly third, round of rating on appropriateness will
occur to determine the final appropriateness ratings.
Elements of Appropriateness Criteria
Development
Indications/Scenarios, Evidence Review,
and Narrative Development
The general indications and their specific scenarios are
selected to reflect specific clinical scenarios for which various
imaging procedures may be considered and that may have a
large impact on patient care. Scenarios will address concepts
such as clinical utility, requisite expertise and indications,
and timing for repeat testing for surveillance or altered
clinical status. Separate clinical indications will be created to
allow for differences in patient risk or disease likelihood
categories and prior test results (e.g., laboratory tests or
electrocardiograms). To help support eventual implementa-
tion, clinical indications should be able to be measured
objectively and contain discrete data elements that are
feasible to collect at the time of ordering.
The narrative and evidence tables for each indication will
summarize the available evidence. They will describe the
strengths and limitations of the evidence favoring organized
research over expert opinion. Stronger study design meth-
Composition
ACR.
erts from cardiology and radiology. Member(s) of the oversight committee are
rovide methodology guidance and continuity. Additional experts in clinical
parative effectiveness, or other content areas are recruited as needed.
lected from societal and stakeholder nominations to broadly represent
nd other groups relevant to the topic.
o order tests, and other expertise; must be an odd number; imaging physicians
% of the panel. Cardiology and radiology may not have equal representation,
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vational series, multicenter series, and randomized or con-
trolled clinical trial data. When studies of the imaging
modality in a specific clinical indication are not present,
relevant publications for related topics or using similar tests
may be included but with the limitations clearly indicated.
A narrative will then be constructed for each broad class
of indications, serving as an objective summary of key
literature. The review of the evidence should include:
1. Clinical rationale—reason for examining the patient
2. Imaging rationale—reason for the use of imaging
3. Literature review summary statement—description of
the clinical performance of each test for the specific
indications. A review of the evidence supporting use of
each imaging modality to understand specific clinical
parameters and the technical capabilities required to
support these uses may be helpful in constructing the
summary statement. This detailed review of imaging
parameters may be provided as an appendix and
examines the role of each parameter in defining
incidence and providing information for diagnosis,
prognosis, and guiding treatment
4. Evidence table—lists key articles from the summary
statement, categorizes study design, and rates the
strength of scientific evidence
To provide a foundation for the writing panel, the
oversight committee develops material providing an over-
view of cardiovascular imaging procedures and safety con-
siderations (see Appendix B). These foundational materials
include a review of the technical capabilities of each test to
examine various clinical parameters, as well as issues related
to patient safety (e.g., radiation exposure, contrast agents,
other pharmaceuticals used during the procedure). These
materials will be referenced, updated, and expanded by the
successive writing panels as required. All documents also are
to assume that the imaging procedures are performed using
Table 2. Appropriateness Categories and Scores
Score Category
1, 2, or 3 Rarely appropriate Rarely an appropriate option
advantage; rarely an effec
clinical reasons for procee
generally reasonable for th
, 5, or 6 May be appropriate At times an appropriate optio
agreement regarding the b
evidence, and/or variabilit
patient’s physician in cons
with patient preferences (i
, 8, or 9 Appropriate An appropriate option for ma
effective option for individ
patient-specific preference
indication).
The rating scale is composed of discreet integers from 1 to 9. The available knowledge base of e
considers the available evidence, which may be limited, unclear, or even conflicting, and using t
modified Delphi technique is robust as a methodology for handling differences in interpretation o
clinical scenario with a rating in the maybe appropriate category may indicate the need for addiaccepted image acquisition protocols, in accredited facilities,using accepted standards of reporting by personnel creden-
tialed to perform and interpret the test.
Review Process
The indications/scenarios, narrative, literature review, and
evidence table are then sent to the review panel, whose
purpose is to ensure the indications are both clear and reflect
clinical practice; and that the literature review provides
sufficient material to facilitate the rating process. The
review panel is expected to suggest indication consolida-
tion and/or expansion, provide additional key references,
and make suggestions to improve overall clarity and
clinical applicability.
Rating Process
The rating panel use a 1 to 9 scale to rate the appropriate-
ness of an imaging procedure for the specific indication/
scenario (Table 2). There are 3 categories that define this
scale, where 1, 2, or 3 represents the “rarely appropriate”
category; 4, 5, or 6 represents the “maybe appropriate”
category; and 7, 8, or 9 represents the “appropriate” cate-
gory. The maybe appropriate category is further specified
into 3 subcategories. The maybe appropriate category indi-
cates that the rating panel agreed that: 1) there was
insufficient evidence on whether the imaging procedure was
appropriate or not; or 2) the available evidence was equiv-
ocal or conflicting; or 3) additional factors beyond those
described must be considered. A maybe appropriate rating is
more likely with procedures using new technology or pro-
tocols for which the evidence is limited and additional
research is required. All raters recognize that a rating in the
maybe appropriate category does not invalidate the use of
specific imaging on a case-by-case basis when the best
interests of an individual patient are being considered by the
caring physician. The ACCF and the ACR recommend
that a maybe appropriate category not be used as justifica-
Description
anagement of patients in this population due to the lack of a clear benefit/risk
tion for individual care plans; exceptions should have documentation of the
ith this care option (i.e., procedure is not generally acceptable and is not
cation).
management of patients in this population due to variable evidence or
/risk ratio, potential benefit based on practice experience in the absence of
e population; effectiveness for individual care must be determined by a
n with the patient based on additional clinical variables and judgment along
ocedure may be acceptable and may be reasonable for the indication).
ent of patients in this population due to benefits generally outweighing risks;
re plans although not always necessary, depending on physician judgment and
procedure is generally acceptable and is generally reasonable for the
for rating each scenario varies from extensive to limited or none. Each member of a rating panel
ertise and experience, determines their individual rating for each modality in the scenario. The
vidence-based and varied expertise among the rating panel members. Imaging procedures for a
vidence to move the rating into either the rarely appropriate or appropriate rating ranges.for m
tive op
ding w
e indi
n for
enefit
y in th
ultatio
.e., pr
nagem
ual ca
s (i.e.,
vidence
heir exption for the nonpayment of imaging services.
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appropriateness of each imaging procedure for all the
clinical indications. The results are then tabulated and
returned to the rating panel members in the form of their
individual scores along with the de-identified scores from
the other members. A mandatory in-person meeting of the
rating panel is then held to review and propose indication
revisions to the writing panel. The in-person meeting
includes nonrating representatives of the writing panel and
oversight committee, who provide guidance relative to
procedural and operational issues and ensure continuity
throughout the process. The oversight committee represen-
tative also serves as an unbiased moderator to the rating
panel and facilitates optimal group dynamics during the
process. The oversight committee moderator must be free of
significant relationships with industry and be unbiased
relative to the topics under consideration. The revised
narrative and indications then undergo a second round of
independent rating. If a significant dispersion of scores is
still present, a conference call and/or third round of rating
will occur. Sufficient agreement is achieved for a topic if
60% of the rating scores fall within 1 of the 3 categories
(e.g., appropriate, maybe appropriate, or rarely appropriate).
Endorsement and Publication
Once the rating process has concluded, additional modifi-
cations of indications, scores, and narrative/evidence tables
are not possible. This critically preserves the integrity of the
Delphi process, which cannot be influenced post hoc. The
final document, including summary tables and/or figures,
will be assembled by the writing panel and submitted to the
oversight committee for approval, and then submitted to the
boards of the ACCF and ACR for approval before publi-
cation. Other societies and organizations may be invited to
endorse the manuscript.
Application of Appropriate Utilization
Documents
Appropriate utilization of imaging is the shared responsi-
bility of clinicians who use imaging to guide clinical decision
making in patient care on one hand, and of physicians who
perform imaging procedures and understand the strengths
and limitations of imaging technology on the other. Ac-
cordingly, these documents are designed to improve clinical
cardiovascular care through judicious use of cardiovascular
imaging. The intended audience for these documents is
diverse, including clinicians, patients, payers, and policy-
makers. Indications do not always require specific imaging,
and procedures rated rarely appropriate may, under certain
circumstances, be fully justified. Possible applications of the
appropriate use documents include incorporation into deci-
sion support systems (including computerized physician
order entry), integration into laboratory accreditation stan-
dards, and as a means to provide critical feedback andeducation to healthcare providers as to appropriate imaging
decision making.
Conclusions
The ACCF and the ACR have collaborated in creating a
rigorous combined method for the development of criteria
for the appropriate utilization of cardiovascular imaging
based on real-world clinical scenarios. The resulting criteria
can be combined with the prior efforts of both organizations
to ensure high value use of cardiovascular imaging.
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APPENDIX A. DEFINITION OF APPROPRIATENESS
AND UNDERLYING METHODOLOGY
The methods presented are based on the Appropriateness
Method originally developed in the 1980s as part of the
RAND Corporation/University of California Los Angeles
(UCLA) Health Services Utilization Study (14) and the
extensive combined experience of the ACR and ACCF in
applying these methods. In their report on the RAND
methodology, Brook et al. defined care as appropriate when
“the expected health benefit (i.e., increased life expectancy,
relief of pain, reduction in anxiety, improved functionalcapacity) exceeded the expected negative consequences (i.e.,
mortality, morbidity, anxietypaintime lost from work) by
a sufficiently wide margin that the procedure is worth doing”
(56, p. 3). Instructions specified that this definition should
be applied exclusive of cost when judging the appropriate-
ness of indications. The AQA Alliance (formerly “Ambu-
latory Care Quality Alliance,” renamed to reflect the expan-
sion of the mission beyond ambulatory care) was formed in
2004. As participants in AQA alliance activities, the ACR
and ACCF base their views of appropriateness on the AQA
alliance’s definition of appropriateness:
The concept of appropriateness, as applied to health care,
balances risk and benefit of a treatment, test, or procedure in
the context of available resources for an individual patient
with specific characteristics. Appropriateness criteria should
provide guidance to supplement the clinician’s judgment as
to whether a patient is a reasonable candidate for the given
treatment, test or procedure (16, para. 2).
The ACCF has modified this concept to include an analysis
of explicit cost in their definition of an appropriate imaging
procedure. The ACCF definition is:
An appropriate imaging study is one in which the expected
incremental information, combined with clinical judgment,
exceeds the expected negative consequences* by a sufficiently
wide margin for a specific indication that the procedure is
generally considered acceptable care and a reasonable ap-
proach for the indication.
*Negative consequences include the risks of the procedure (i.e.,
radiation or contrast exposure) and the downstream impact of
poor test performance such as delay in diagnosis (false negatives)
or inappropriate diagnosis (false positives) (7, p. 1607).
The Appropriateness Method relies on the tenets of
evidence-based medicine to integrate scientific evidence and
expert opinion (15,16). The Appropriateness Method is
different from “consensus methods” in that the objective is
not to develop a consensus among experts but to see
whether experts agree or disagree, and to what extent, given
the available evidence. The Appropriateness Method is an
extension of the Delphi method, also developed by the
RAND Corporation, for predicting future events. In the
modified Delphi method, material is circulated among a
group of experts who are asked to rate various scenarios.
These answers are tabulated and presented to the group
for discussion before each additional round for a maxi-
mum of 3 rounds.
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Modality Variations Contrast/Isotope Contrast Agent
Potential Contrast-
Related Issues Cannulation Needs
Potential
Cannulation-
Related
Issues
Other Potential
Issues
Radiation Exposure
Ranges
(mSv)
Echocardiography Transthoracic Infrequent Microbubble Reaction (5,18–20) Venous for contrast Peripheral vein
injury (21)
NA NA
Exercise stress contraction
transthoracic
()/() Microbubble Reaction (5,18–20) Venous for
medications/
contrast
Peripheral vein
injury (21)
Stress-related
(22)
NA
Pharmacological stress
contraction
transthoracic
()/() Microbubble Reaction (5,18–20) Venous for
medications/
contrast
Peripheral vein
injury (21)
Stress-related
(22)
NA
Transesophageal () NA NA Esophageal for
probe
Esophageal
perforation
(23,24)
Sedation (25) NA
Venous for
medications
Peripheral vein
injury (21)
MR Anatomic/functional ()/() Gadolinium Reaction (26–28)
NSF (29–31)
Venous for contrast Sedation (25)
Tissue burn/
metallic
attraction/
electronic
dysfunction
(32–34)
NA
Pharmacological stress/
rest perfusion
() Gadolinium Reaction (26–28)
NSF (29–31)
Venous for
medications/
contrast
Medication-
related
Tissue burn/
metallic
attraction/
electronic
dysfunction
(32–34)
NA
Pharmacological stress
contraction
() NA NA Venous for
medications
Peripheral vein
injury (21)
Stress-related
(35)
Medication-
related
Tissue burn/
metallic
attraction/
electronic
dysfunction
(32–34)
NA
CT Enhanced () Iodine Reaction
(21,26,36,37)
CIN (21,38–40)
Venous for
medications/
contrast
Peripheral vein
injury (21)
Medication-
related
1–28 mSv
(41–50)
PECT Rest perfusion NA NA NA Venous for
radionuclide
Peripheral vein
injury (21)
NA 4–20 mSv
(42,43,49–51)
Pharmacological stress/
rest perfusion
Technetium,
thallium, etc.
NA NA Venous for
medications/
radionuclide
Medication-
related
9–41 mSv
(42,43,49–51)
ET Rest perfusion Rubidium, etc. NA NA Venous for
radionuclide
Peripheral vein
injury (21)
NA 5–8 mSv
(42,43,49–51)
Pharmacological stress/
rest perfusion
NA NA NA Venous for
medications/
radionuclide
Peripheral vein
injury (21)
Medication-
related
10–16 mSv
(42,43,49–51)
Rest metabolism NA NA NA Venous for
radionuclide
Peripheral vein
injury (21)
NA 7–14 mSv
(42,43,49–51)
nvasive coronary
angiography
Left heart () Iodine Reaction
(21,26,36,37)
CIN (21,38–42)
Arterial for contrast
Venous for
medications
Coronary/aortic/
peripheral
artery
injury
(52–54)
Peripheral vein
injury (21)
Sedation (25)
Embolization
Ventricular
arrhythmia
(52–54)
2–23 mSv
(43,55)
Right heart () Iodine Reaction
(21,26,36,37)
CIN (21,38–40)
Venous for
medications/
contrast
Coronary/caval/
peripheral
vein injury
(21,52–54)
CCT  cardiac computed tomography; CIN  contrast-induced nephropathy; CMR  cardiac magnetic resonance; NA  not applicable; NSF  nephrogenic systemic fibrosis; PET  positron emission
tomography; SPECT  single-photon emission computed tomography.
